Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
Crossref DOI link: https://doi.org/10.1007/s10549-016-4001-y
Published Online: 2016-10-06
Published Print: 2016-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tolaney, Sara M.
Nechushtan, Hovav
Ron, Ilan-Gil
Schöffski, Patrick
Awada, Ahmad
Yasenchak, Chris A.
Laird, A. Douglas
O’Keeffe, Bridget
Shapiro, Geoffrey I.
Winer, Eric P.
Funding for this research was provided by:
Exelixis
License valid from 2016-10-06